NCT07020793

Green Subthreshold Laser Therapy for Chronic Central Serous Chorioretinopathy.

Efficacy of Green Subthreshold Laser Therapy in the Treatment of Chronic Central Serous Chorioretinopathy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 12 (actual)
• Sponsor: Federico II University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Chronic Central Serous Chorioretinopathy (CSCR) is a vision-threatening retinal disorder characterized by persistent subretinal fluid due to choroidal vascular hyperpermeability and retinal pigment epithelium (RPE) dysfunction. This study evaluates the efficacy and safety of green subthreshold laser therapy using Norlase µSec Technology as a novel, tissue-sparing approach for treating chronic CSCR. By targeting RPE repair without inducing visible retinal damage, this technique aims to resolve subretinal fluid, restore retinal architecture, and improve visual function. This is the first study to report clinical outcomes with this specific laser platform in chronic CSCR management.

Conditions

• the Presence of Subretinal Fluid (SRF)

Interventions

Type	Name	Description
PROCEDURE	green subthreshold laser therapy	The intervention consists of green subthreshold laser therapy delivered using the Norlase µSec™ Technology, a novel microsecond-pulsed laser platform specifically designed for retinal treatments.

Timeline

• Start date: 2024-06-01
• Primary completion: 2024-06-01
• Completion: 2025-03-30
• First posted: 2025-06-13
• Last updated: 2025-06-13

Locations

1 site across 1 country: Italy